Zelgen Biopharmaceuticals Submits BLA for Innovative rhTSH Product

2024-06-05

临床3期上市批准申请上市

June 5, 2024 - In a significant development for the pharmaceutical industry, Zelgen Biopharmaceuticals has announced the submission of a Biologics License Application (BLA) to the National Medical Products Administration (NMPA) for its self-developed injectable recombinant human thyroid-stimulating hormone (rhTSH). The product is currently awaiting formal acceptance for review.

The submitted application targets an important indication - the use of rhTSH in radioactive iodine (131I) whole-body scanning (WBS) and serum thyroglobulin (Tg) testing for follow-up of differentiated thyroid cancer patients who have undergone prior thyroidectomy. This represents an unmet need in the Chinese market, as no recombinant human thyroid-stimulating hormone has yet been approved for this specific application.

The announcement has been welcomed by the market, with Zelgen Biopharmaceuticals's stock price soaring over 60% since its February low. This milestone marks the company's fourth product to reach the New Drug Application (NDA) stage, underscoring its robust pipeline and innovative capabilities.

Thyroid cancer is on the rise globally, and the unique advantages of thyroid-stimulating hormone in cancer management make this a highly promising market opportunity. Currently, only Sanofi's Thyrogen, a recombinant human TSH, is approved in the United States, while the original Thyrogen has faced manufacturing challenges in gaining approval in mainland China.

Zelgen Biopharmaceuticals's rhTSH and Suntory Biotech's SNA001 (approved in April 2024) are the two domestic players in the Chinese rhTSH market. Notably, the companies have chosen different initial indications, with SNA001 focusing on thyroid cancer treatment and Zeria's rhTSH targeting post-surgical diagnostic applications. This strategic positioning helps mitigate competitive risks in the emerging market.

With the submission of the BLA and the positive results from its Phase III ZGTSH004 trial, Zelgen Biopharmaceuticals is well-positioned to capitalize on the growing demand for innovative thyroid cancer management solutions in China. The company's pipeline and stock performance suggest more exciting developments are in store for the industry and investors alike.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构